Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Trial Parameters
Brief Summary
This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.
Eligibility Criteria
Inclusion Criteria: * Patients with idiopathic cytopenias of unclear significance (ICUS) * Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic) * Patients with clonal cytopenias of undetermined significance (CCUS) * Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders * Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc. * Low risk MDS (idiopathic dysplasia of unclear significance) * Family member of a patient with one of the above conditions * Patient at high risk or suspected of developing one of the above conditions Exclusion Criteria: * Patients under 18 years of age